Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The ocular surface tear film and mucous layer is a complex, dynamic fluid system that covers the cornea and conjunctiva, serving as the primary interface between the eye and the environment. It is traditionally described as a tri-layered structure consisting of an outer lipid layer (produced by meibomian glands), a middle aqueous layer (produced by lacrimal glands), and an inner mucin layer (secreted by goblet cells), though modern models describe it as a unified mucoaqueous gel (TFOS DEWS II, 2017). This system is vital for maintaining a smooth refractive surface for clear vision, providing lubrication to minimize friction during blinking, and delivering oxygen and nutrients to the avascular corneal epithelium (StatPearls, 2023). In pathological states such as Dry Eye Disease (DED), the tear film loses homeostasis, leading to hyperosmolarity and inflammation that can damage the ocular surface (NIH, 2022). Therapeutic strategies targeting this system include the use of lubricants to replenish volume, lipid-based emulsions to reduce evaporation, and anti-inflammatory agents like cyclosporine to improve the quality and quantity of natural tear production (PubMed, 2021). Effective management of the tear film is essential for preventing corneal scarring and maintaining long-term visual acuity.
The mechanism of action involves the supplementation of tear volume, stabilization of the lipid layer to prevent evaporation, and the reduction of ocular surface inflammation to restore the homeostatic environment of the tear film (StatPearls, 2023; TFOS DEWS II, 2017).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ocular surface tear film and mucous layer (PTF).